SAFETY AND EFFICACY RESULTS FROM A PHASE 1/1B STUDY OF INTRATUMORAL MK-4621, A RETINOIC ACID-INDUCIBLE GENE I (RIG-I) AGONIST, PLUS INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Moreno, Victor [1 ]
Gaudy-Marqueste, Caroline [2 ]
Wermke, Martin [3 ]
Italiano, Antoine [4 ]
Romano, Emanuela [5 ]
Marabelle, Aurelien [6 ]
Connors, Emilee [7 ]
Zhou, Heng [7 ]
Dobrenkov, Konstantin [7 ]
Chartash, Elliot [7 ]
Calvo, Emiliano [8 ]
Calvo Aller, Emiliano [8 ]
机构：
[1] Hosp Univ Fdn Jimenez, ISTART Madrid FJD, Madrid, Spain
[2] Timones Hosp, CEPCM CLIP2, Marseille, France
[3] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[4] Inst Bergonie, Bordeaux, France
[5] Inst Curie, Paris, France
[6] Inst Gustave Roussy, Villejuif, France
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Ctr Integral Onco, START Madrid CIOCC, Madrid, Spain
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0794
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
794
引用
收藏
页码：A474 / A475
页数：2
相关论文
共 50 条
  • [1] Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors
    Middleton, M. R.
    Wermke, M.
    Calvo, E.
    Chartash, E.
    Zhou, H.
    Zhao, X.
    Niewel, M.
    Dobrenkov, K.
    Moreno, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    V. Moreno
    E. Calvo
    M. R. Middleton
    F. Barlesi
    C. Gaudy-Marqueste
    A. Italiano
    E. Romano
    A. Marabelle
    E. Chartash
    K. Dobrenkov
    H. Zhou
    E. C. Connors
    Y. Zhang
    M. Wermke
    Cancer Immunology, Immunotherapy, 2022, 71 : 2985 - 2998
  • [3] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    Moreno, V
    Calvo, E.
    Middleton, M. R.
    Barlesi, F.
    Gaudy-Marqueste, C.
    Italiano, A.
    Romano, E.
    Marabelle, A.
    Chartash, E.
    Dobrenkov, K.
    Zhou, H.
    Connors, E. C.
    Zhang, Y.
    Wermke, M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (12) : 2985 - 2998
  • [4] A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
    Lakhani, Nehal J.
    Burris III, Howard
    Miller Jr, Wilson H.
    Huang, Mo
    Chen, Lin-Chi
    Siu, Lillian L.
    INVESTIGATIONAL NEW DRUGS, 2024, : 581 - 589
  • [5] Cell Type-Specific Recognition of Human Metapneumoviruses (HMPVs) by Retinoic Acid-Inducible Gene I (RIG-I) and TLR7 and Viral Interference of RIG-I Ligand Recognition by HMPV-B1 Phosphoprotein
    Goutagny, Nadege
    Jiang, Zhaozhao
    Tian, Jane
    Parroche, Peggy
    Schickli, Jeanne
    Monks, Brian G.
    Ulbrandt, Nancy
    Ji, Hong
    Kiener, Peter A.
    Coyle, Anthony J.
    Fitzgerald, Katherine A.
    JOURNAL OF IMMUNOLOGY, 2010, 184 (03): : 1168 - 1179
  • [6] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [7] Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph P.
    Riedell, Peter A.
    Fleury, Isabelle
    Du, Yan
    Han, Xia
    Pearson, David
    Redondo, Santiago
    Waller, Edmund K.
    BLOOD ADVANCES, 2023, 7 (11) : 2283 - 2286
  • [8] Safety and efficacy of Pembrolizumab (MK-3475) for Japanese patients (pts) with advanced melanoma: Preliminary results from KEYNOTE-041 Phase 1b study
    Yokota, K.
    Takenouchi, T.
    Fujimoto, M.
    Ihn, H.
    Uchi, H.
    Inozume, T.
    Kiyohara, Y.
    Uhara, H.
    Nakagawa, K.
    Furukawa, H.
    Wada, H.
    Noguchi, K.
    Shimamoto, T.
    Yamazaki, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S672 - S672
  • [9] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [10] Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study
    Naing, Aung
    Mamdani, Hirva
    Barve, Minal A.
    Johnson, Melissa Lynne
    Morgensztern, Daniel
    Olszanski, Anthony J.
    Wolff, Robert A.
    Pant, Shubham
    Chaney, Marya F.
    Adebanjo, Tolani
    Fan, Jean
    Kim, Richard D.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345